Nebenwirkungen · Spravato
Spravato 28 mg nasal spray, solution · Abschnitt 4.8 · PDF-Seite 10
HOS-139764 · Präparat HOS-098400
Changes in blood pressure In clinical trials for treatment-resistant Major Depressive Disorder, increases in systolic and diastolic blood pressure (SBP and DBP) over time were about 7 to 9 mmHg in SBP and 4 to 6 mmHg in DBP at 40 minutes post-dose and 2 to 5 mmHg in SBP and 1 to 3 mmHg in DBP at 1.5 hours post-dose in patients receiving Spravato plus oral antidepressants (see section 4.4). The frequency of markedly abnormal blood pressure elevations of SBP (≥40 mmHg increase) ranged from 8% (<65 years) to 17% (≥65 years) and DBP (≥25 mmHg increase) ranged from 13% (<65 years) to 14% (≥65 years) in patients receiving esketamine plus oral antidepressant. The incidence of increased SBP (≥ 180 mmHg) was 3% and DBP (≥ 110 mmHg) was 4%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-23T12:42:00Z · SHA-256 66d3d2c4bc9c09be85b3106118aac863d6fcc4a754ee8fa4571517590a96c3b9 · Passage 1e3b4da0c25f55db7c263b017476d9e957bc321cfd88fc5e4e8a98a9a1821745 · Zeichen 6550–7290 im Abschnitt